“showed a trend”

Subgroup analysis showed a trend that persisted in longer PFS and OS benefits with Group A compared to Group B ( Figures 4 , 5 ).

The difference between Group 1 and Group 2 showed a trend but did not reach statistical significance after correction ( p = 0.065).

Another item, “ability to select healthful foods,” showed a trend toward improvement but was non-significant ( p = 0.06).

Although patients using Tα1 showed a trend toward lower incidence of IPN compared to those using a placebo during hospitalization (15.7% vs 18.1%) and within 90 days after randomization (22.4% vs 25.6%), there was a lack of statistical difference.

All fabrics tested showed a trend towards increased elongation of the fibers due to the modification process ( Table 3 ).

The curve showed a trend of increasing flexural strength and Young’s modulus with increasing the GF ratio.

This analysis showed a trend toward improved RFS for patients who did receive alloHSCT after blinatumomab treatment compared with patients who did not.

MRPL12, POLG‐2, POLG‐4, POLG‐8, and POLG‐9 showed a trend toward cytosolic mtDNA leakage (Figure 3C ).

6 F), showed a trend toward higher expression of the mesoderm marker Brachyury(T), the cardiac progenitor marker NKX2.5, and the cardiac marker TNNT2 in mRNA expression at day 12 of differentiation induction (Fig. 6 B).

control 13%, P = 0.048) and showed a trend towards higher composite treatment failure (BPAR, graft loss, death, loss to follow-up).

The combined incidence of HFS-related AEs (‘HFS’ or ‘rash hand foot skin reaction’) showed a trend in favour of pyridoxine use: any grade was 51% vs 53% (odds ratio 0.93, 95% CI 0.43–2.0) whereas grade 3/4 was 9% vs 17% (odds ratio 0.51, 95% CI 0.15–1.6).

The desire for a more effective method showed a trend towards increased discontinuation, but with a less significant impact (HR = 0.829, 95% CI: 0.461, 1.197).

Although not statistically significant, maternal low birth weight and/or preterm birth showed a trend toward a higher risk of a composite outcome, with an aRR and aRD of 1.46 (95% CI: 0.99–2.06) and 13.7% (95% CI: −1.8 to 29.2%), respectively.

While not statistically significant, additional Western Blot analysis of autophagy-associated p62 protein levels showed a trend of decreased p62 levels in ICI treated hearts, potentially suggesting increased p62 degradation and enhanced autophagy.

An intra-individual comparison showed a trend towards greater strength in the right hand, though it was statistically insignificant.

In contrast, we did not observe a state-by-metric interaction in the SUB, likely because the subnetwork-wise local efficiency also showed a trend indicating an increase.

Thus, patients with more frequent visits showed a trend towards a higher rate of TL.

Results Our results showed a trend for reduced β-hCG levels in the GDM group compared to the control group, but these levels tended to be higher in the GDM subgroup treated with insulin.

RCT showed a trend of toxicities increase compared with RT, however, the toxicities were tolerable and manageable.

After correction for multiple testing, the enrichment in gWAT and skeletal muscle was still significant (p-values: 0.006, 0.046 respectively); liver genes showed a trend for enrichment (p-value: 0.064).

The data from ThT experiments showed a trend of increasing affinities in the order OH (HMB) > NO 2 (NMB) > NH 2 (AMB) (Table S2 ).

Consistently, a study in patients up to 10 years following radiochemotherapy, showed a trend towards worse survival when tumor cells expressed VEGF-A and VEGFR-1 [ 201 ].

Non-specific ST-T wave changes and first degree atrioventricular block were significantly associated with elevated right ventricular systolic pressure on echocardiogram while RBBB and ECG findings indicative of pulmonary hypertension showed a trend for association with this echocardiographic finding.

Late-Pro patients showed a trend toward improved outcomes with imatinib-only therapies.

Furthermore, our results showed a trend towards higher weight-based dosing of GCs in younger children with SLE.